ANZCTR search results

The purpose of this study is to review the use of Vinorelbine as a chemotherapy treatment option in patients post immunotherapy for metastatic non-small cell lung cancer (NSCLC). Who is it for? You may be eligible for this study if you, have received immunotherapy for metastatic NSCLC and are a patient at one of the participating sites. Study details Participants in this study will continue to receive routine clinical care, which will not be impacted by involvement in this study. Enrolled participants will have clinical data collected at one time point from their medical record. Data will be collected on the tolerability and duration of Vinorelbine chemotherapy when used following immunotherapy treatment in patients with metastatic NSCLC. It is hoped this research will offer insight into the use of Vinorelbine as a potentially beneficial treatment option for patients with metastatic NSCLC in the post immunotherapy setting.

A randomised double-blind placebo-controlled study to evaluate the effect of curcumin on BDNF levels in otherwise healthy adults. The aim of this study is to assess the effectiveness of a bioavailable form of curcumin on BDNF levels compared to a placebo in otherwise healthy adults aged between 18 and 40 years old.

The purpose of this study is to assess the safety, tolerability of the drug INCB086550 and assess how this drug acts in the body with and without food and in combination with other drugs. who is it for? You may be eligible for this study if you are a male or female, aged 18 to 55, and you are in good health with no existing conditions. Study Details In Cohort 1 all participants will receive a single dose of the drug (orally in a fasted (no food) or fed (med calorie food) condition in Periods 1 and 2 by random assignment. In Cohort 2 through 5 subjects will be dosed with INCB086550 in combination with other drugs specified earlier. It is hoped this research will provide information as to how this drug acts in the body in fed and fasted conditions and in combination with other drugs, results from the study will affect how patients with cancer use this medication

CALM-GUT study is an observational study that aims to evaluate cannabinoid based medicines as a potential therapy for reducing symptoms of irritable bowel syndrome (IBS). Patients over 18 years of age who attend Emerald Clinics for treatment of IBS symptoms with cannabinoid based medicines will be offered participation in the study. Patients are observed for 12 weeks, using a combination of validated questionnaires, self-reported symptoms, and regular follow up with a specialist GP or gastroenterologist. Baseline symptoms and responses to questionnaires will be compared to results after 12 weeks to determine if the treatment is safe and effective in this patient cohort.

This is a single center, open-label, study of rosuvastatin 140 mg ER capsules (LYN-047) to evaluate its safety, tolerability, and PK when administered as 2 weekly doses in healthy male and female volunteers.

Stroke is the third leading cause of death in Australia. Ischaemic stroke accounts for ~80% of all stroke cases and is caused by a narrowing or obstruction of the blood vessels resulting in oxygen and nutrient deprivation. Conventional post-stroke management involves combining pharmacotherapy and rehabilitative therapies. Nao Xin Qing (NXQ) is a TGA-approved product (AUSTL196297) in Australia. NXQ is a novel herbal formula made from the standardised extract of persimmon leaves. NXQ has been used clinically in China for numerous years in the treatment of apoplexy, coronary heart disease and enhance recovery from ischemic stroke. The aim of this randomised double-blind controlled study is to assess the clinical effectiveness of NXQ for ischaemic stroke patients during rehabilitation phase. This will provide preliminary data whether NXQ can be used as an effective treatment of ischaemic stroke recovery, to prevent recurrence of stroke and improve quality of life of stroke survivors.

To date, nutrition research in critical illness has focused on the acute early period of illness, when metabolic changes and catabolism occurs. However, despite much research, no large-scale randomised controlled trial (RCT) has demonstrated a clear benefit for nutrition interventions delivered early and for a short duration in the Intensive Care Unit (ICU). Limited work investigating nutrition in the post-ICU phase of illness has been conducted to date, but what is known consistently shows (across many different populations) that intake in this period is below clinician estimates. These shortfalls in nutrition adequacy across acute hospitalisation (and if these shortfalls continue to the sub-acute setting also), may have the potential to impact long-term recovery following critical illness although investigation in this area is lacking. The aim of this study is to describe the nutrition process of care in critically ill adult patients from ICU admission until discharge from inpatient rehabilitation. This study is a single-centre retrospective observational study conducted at an acute care hospital and subacute inpatient facility within Alfred Health, including adult patients aged 18 years and above, who had an ICU admission at The Alfred Hospital for more than 48 hours with discharge to Caulfield Hospital inpatient rehabilitation within 28 days during index hospitalisation admission.

The patients from which this data will be drawn were referred to the clinic by their general practitioner with symptomatic joint osteoarthritis for whom injection of hyaluronic acid (Durolane) was found to be the most appropriate treatment. This data is collected on all patients undergoing such injections as a routine pre and post injection measures of their pain and function. For those who had more than one injection, the time in days between injections will be analysed. Patient data will be included in the analyses if they were >18 years old with painful hip osteoarthritis and mild to moderate radiological changes on their imaging. There was no maximum age limit applied to the inclusion criteria. There were no specific inclusion or exclusion criteria in regards to race and gender. The current data set of the patient cohort intended for analysis was collected over 4 years.The data from these patients who have recieved Durolane injections in normal clinical practice will be analysed retrospectively.

The purpose of this research is to assess the effectiveness of a 16-week web-based low carbohydrate diet program for adults with type 2 diabetes, toward facilitating improvements in glycaemic control, assessed on primary outcome HbA1c. In addition, dietary intake data and self-efficacy will be assessed, along with changes in weight, anti-diabetes medication and diabetes-related comorbidities. Study recruitment will occur online across Australia, with the aim of recruiting 100 adults with non-insulin dependent type 2 diabetes aged between 40-89 years. Participants will be randomised to standard care plus web-based intervention or standard care only. Participants will be provided with login details to the intervention website to access weekly structured behaviour change modules and on demand resources that assist participants to practically implement a low carbohydrate diet. An assessment of participants' experience of and engagement with the intervention will also be explored after the intervention.

This pilot study will assess if blocking the blood supply to part of the stomach (known as a left gastric artery embolisation procedure) is feasible and can be performed safely in a small group of obese patients who are awaiting elective surgery. Blocking up the blood supply to a portion of the stomach reduces the production of the hormone that stimulates appetite (called ghrelin). Lower ghrelin levels in the blood stream have been shown to reduce the "hunger drive" and consequently reduce calories consumed, making dieting more effective and speeding up weight-loss. It is common for elective surgery in obese people to be delayed until they lose weight, and this procedure may help these patients to reach their weight-loss goals earlier. This study may provide information necessary to complete larger studies assessing the effectiveness of left gastric artery embolisaton as a complimentary weight loss technique.